Navigation Links
New Drug Shows Promise Against Huntington's Disease
Date:11/7/2011

MONDAY, Nov. 7 (HealthDay News) -- An investigational drug called pridopidine seems an effective and safe treatment for people with the progressive movement disorder Huntington's disease, researchers report.

Huntington's patients have an imbalance in the signaling chemical dopamine. The new drug stabilizes dopamine signaling in areas of the brain that control movement and coordination.

According to the study authors, this is the first drug shown to improve patients' loss of ability to move their muscles voluntarily. The only drug currently approved for Huntington's is tetrabenazine, which treats only involuntary movements and can cause serious side effects.

The results of the phase 3 clinical trial, conducted by Spanish researchers led by Dr. Justo Garcia de Yebenes, of the department of neurology, Hospital Ramon y Cajal in Madrid, appear in the Nov. 7 online edition of The Lancet Neurology.

The study included 437 Huntington's disease patients from eight European countries. The participants took either pridopidine (45 milligrams once daily or 45 mg twice daily) or a placebo for 26 weeks.

After six months of treatment, patients taking the higher dose of pridopidine showed improvements in motor function -- specifically in eye and hand movements, involuntary muscle contractions (dystonia), and gait and balance -- compared with patients taking the placebo.

More than 70 percent of the patients taking the higher dose of the drug showed a significant benefit, according to the researchers. Side effects among patients taking the drug were similar to the placebo group.

"Pridopidine has the potential to complement available treatments by improving a different range of motor deficits. Its lack of severe side-effects . . . suggests that pridopidine might be useful even for those patients who are treated at sites that are not centers of excellence for Huntington's disease," the researchers concluded.

One U.S. neurologist agreed that the drug seems promising against a disease with few treatment options.

"There has been a great deal of attention for this drug, as it is one of the few molecules that in preliminary studies was found to have some efficacy in Huntington's disease," said Dr. Alessandro Di Rocco, professor in the department of neurology and chief of the division of movement disorders at NYU Langone Medical Center in New York City.

"However, this is the first large study to show evidence of a positive result in treating the motor symptoms of this devastating disease. And, though the compound is apparently well tolerated without significant side effects, the benefit is modest and limited to the motor symptoms of the disease and it is unknown how long the improvement observed could last," he added.

Still, pridopidine does not get at the underlying cause of Huntington's disease, Di Rocco said.

"Unfortunately, Huntington's is a progressive disease and this drug is not a treatment of the disease itself but only improves some of its symptoms," he explained. "Nevertheless, it is a welcome addition because there is very little else yet available to treat the symptoms. The challenge for scientists and clinicians is to discover therapies that actually slows or halts the progression of the disease."

Another expert agreed that new treatment options for patients are sorely needed.

"A well-tolerated drug that produces even small benefits for patients with Huntington's disease would be a very welcome addition to the currently available treatments for this debilitating disorder," Andrew Feigin, from The Feinstein Institute for Medical Research in New York City, wrote in an accompanying commentary.

The study was funded by European pharmaceuticals company NeuroSearch A/S.

More information

We Move has more about Huntington's disease.

-- Robert Preidt

SOURCES: Alessandro Di Rocco, M.D., professor, department of neurology and chief, division of movement disorders, NYU Langone Medical Center, New York City; The Lancet Neurology, news release, Nov. 7, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Gene therapy shows promise as hemophilia treatment in animal studies
2. Exenatide (Byetta) has rapid, powerful anti-inflammatory effect, UB study shows
3. New drug shows promise against multiple sclerosis
4. Preterm birth rate shows three year improvement in most states
5. Study shows no increased risk of breast cancer for non-carriers in families with BRCA gene mutation
6. Novel approach to treat proliferative vitreoretinopathy shows promise
7. New therapy shows promise for treating cardiovascular disease
8. More Evidence Shows Newer Forms of Pill Raise Clot Risk, FDA Says
9. New oncolytic virus shows improved effectiveness in preclinical testing
10. Clinical trial shows first evidence that anal cancer is preventable
11. Through-the-nipple breast cancer therapy shows promise in early tests
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug Shows Promise Against Huntington's Disease
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... AxoGen, Inc. ... will report results for the fourth quarter and full year ended December 31, 2015 ... a conference call and webcast for the investment community following the release at 4:30 ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... measure change in their patients. Research shows that the Goal Attainment Scale (GAS) ... therapists overcome this challenge and learn more about the Goal Attainment Scale, Education ...
(Date:2/10/2016)... Palm Beach, Florida (PRWEB) , ... February 10, ... ... & Country Club) announced that it has been awarded the prestigious Distinguished Emerald ... the World award program conducted by BoardRoom magazine, one of the most respected ...
(Date:2/10/2016)... ... February 10, 2016 , ... The ... 26th: Amateur & Professional Divisions - Time: 7:00pm – 10:00pm | Ticket ... Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org , Facebook: http://www.facebook.com/uspolesportsfederation , ...
(Date:2/10/2016)... ... February 10, 2016 , ... The recreational use of marijuana has been ... still face a lot of restrictions as to where they can smoke pot. ... use” and that cannabis “may not be consumed openly or publicly.” , Given the ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... February 10, 2016 Demonstrates ... 1 receptor selectivity   1 ... which has entered clinical development as a new ... and schizophrenia.   --> 1 ... has entered clinical development as a new treatment ...
(Date:2/9/2016)... Feb. 9, 2016  Landauer, Inc. (NYSE: LDR ... measurement and monitoring, outsourced medical physics services and high ... its fiscal 2016 first quarter ended December 31, 2015. ... Fiscal 2016 First Quarter Highlights , Revenue of ... quarter of 2015 , Domestic Radiation Measurement services revenues ...
(Date:2/9/2016)... BioSciences, Inc. (NASDAQ: SGMO ), the leader ... quarter and full year 2015 financial results and ... editing," said Edward Lanphier, Sangamo,s president and chief ... leads the therapeutic genome editing field and we ... our ground-breaking genome editing programs through IND enabling ...
Breaking Medicine Technology: